Delayed Function of Renal Transplant
Conditions
Keywords
Kidney Transplant, Delayed Graft Function
Brief summary
The purpose of this study is to determine if Eculizumab is safe and effective in the prevention of delayed graft function following deceased donor kidney transplantation.
Detailed description
Based on experimental data and supportive observations in humans associating complement gene upregulation with ischemic reperfusion injury, it is hypothesized that C5 cleavage is a key step in the pathogenesis of ischemic reperfusion injury following transplantation. It is further hypothesized that eculizumab, an antibody that blocks C5 cleavage in humans will be an effective prophylactic agent to prevent ischemic reperfusion injury in high risk recipients. To test this hypothesis, this study is a pilot prospective, randomized study to test the efficacy of eculizumab vs. placebo given once at the time of transplantation in preventing delayed graft function in first adult recipients of deceased donor kidneys.
Interventions
DRUGEculizumab
1200 milligrams Eculizumab diluted in 0.9% NaCl to 5mg/mL for a total volume of 240 mL administered by IV infusion over 35 minutes in the operating room prior to organ reperfusion
DRUGPlacebo
240 mL of 0.9% Sodium Chloride IV fluid given as placebo in the operating room prior to organ reperfusion
Sponsors
Alexion Pharmaceuticals, Inc.
Schroppel, Bernd, M.D.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age 18 or older * Weight \> 40 kg * Male or Female * Recipients of first deceased donor kidneys * Able to provide written informed consent * Transplant candidate as per site specific guidelines * Dialysis dependent renal failure (initiated more than 2 months prior to transplant) * Novartis Delayed Graft Function Score 3-8 * Extended criteria donor with brain death, or standard criteria donor with cold ischemic time \< 24 hours
Exclusion criteria
* Planned to receive multi-organ transplant * Kidneys from donors \< 6 years of age * Dual kidney transplant (from same donor, including en bloc) * Living donor kidney * Highly sensitized recipients (PRA \> 50%) * Previous transplant * Participation in another investigational trial * Recipient BMI \> 40 * ABO incompatible * DCD Donor * Preemptive kidney transplant * Recipients with DGF scores \< 3 or \> 8 * Women who are pregnant or breast feeding * Women of child bearing potential who are unable or unwilling to use a medically acceptable form of contraception * Patients infected with HIV, HCV or HBV * Active bacterial or other infection which is clinically significant in the opinion of the investigator * Patients with history of splenectomy * Patients with history of meningococcal disease * Patients with known or suspected hereditary complement deficiency * Patients with history of cancer (other than non-melanoma skin cancers) within the last 5 years
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Composite of Delayed Graft Function and Slow Graft Function | Up to 6 months | Delayed Graft Function defined as follows: 1. A need for at least one dialysis treatment during the first 7 days after transplantation (not including a single session for hyperkalemia or hypervolemia in the first 48 hours) 2. A less than or equal to 50% reduction in serum creatinine in the first 24 hours post-transplantation 3. A serum creatinine reduction ratio \< 30% at 48 hours post-transplantation Slow Graft Function Defined as Follows: A functioning graft at Day 5 Post-transplantation with a serum creatinine \> 3 mg/dL and no need for dialysis |
Countries
United States
Outcome results
None listed